Tribun Health Achieves ISO/IEC 27001 Certification, Strengthening Commitment to Data Security in Digital Pathology
Tribun Health, a leader in digital pathology software and AI-powered diagnostic solutions, is proud to announce that it has been awarded the ISO/IEC 27001 certification-an internationally recognized standard for information security management systems (ISMS).
This achievement underscores Tribun Health's ongoing commitment to the highest standards of data protection, patient confidentiality, and operational excellence. In a field where security and privacy are non-negotiable, ISO 27001 certification validates that the company has implemented a robust framework to identify, manage, and reduce risks to sensitive information.
"Our clients trust us with more than just images-they trust us with lives," said Zina Hamoumi, Chief Operating Officer at Tribun Health. "Achieving ISO 27001 reflects the discipline, structure, and dedication our teams bring to protecting that trust every single day."
"This certification is not just a badge-it's a reflection of our core values," added Jean-François Pomerol, CEO of Tribun Health. "As we continue expanding globally, we remain deeply committed to earning and maintaining the confidence of our partners, customers, and the patients they serve."
Used by pathology labs, hospitals, and healthcare networks worldwide, Tribun Health's CaloPix® platform manages millions of digital slides annually. As data volumes grow and collaboration across institutions increases, the need for stringent, transparent security measures becomes even more critical. ISO 27001 certification confirms that Tribun Health meets those standards, offering peace of mind to healthcare professionals and IT departments alike.
Tribun Health continues to expand its footprint across Europe, North America and other regions, providing digital pathology platforms that are not only innovative but also safe and dependable. This certification builds on Tribun Health's long-standing commitment to data security, offering formal recognition of the rigorous controls already in place.
About Tribun Health
Tribun Health is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.
Contact Information
Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474
SOURCE: Tribun Health
press release
This story was originally published May 6, 2025 at 8:06 AM.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Theraclion Growth Up in S1 2025
MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reviews its business for S1 2025. Sales of consumables (recurring revenue) up 30% compared to 2024 New treatment centers opened in Bulgaria and Spain Appointment of a new business manager and acceleration of commercial activities On-schedule completion of the follow-up period for the pivotal FDA clinical trial Martin Deterre, CEO of Theraclion, states: "In early 2025, Theraclion stepped up Sonovein's activity. In June, the final 12-month follow-ups for patients in the pivotal FDA-approved clinical trial were completed on-schedule. We are now awaiting the final results, which we expect to publish in September. Theraclion has also entered a business development phase: building a sales and marketing team, opening two new Sonovein treatment centers, and achieving significant growth in recurring revenue — all of which promise the achievement of our ambitious goals." Commercial activity acceleration As part of its business development, Theraclion is actively building its sales and marketing team. In May 2025, Thibault Le Normand joined the company as Chief Business Officer to boost sales in the Middle East and product placements (PPUs) of Sonovein in Europe. With over a decade of experience in international development of medical devices, Thibault Le Normand brings valuable expertise to this strategic growth phase. At the same time, the technological credibility and clinical maturity of Sonovein have been further demonstrated by the publication of new scientific articles as well as by over a dozen presentations at major international congresses by renowned physicians using the device. Sonovein's international profile has also increased through Theraclion's participation in congresses, such as Vein in Venice (April, Venice), Venous Symposium (May, New York), and the European Venous Forum (June, Krakow). This outreach effort was supported by the launch of a new product identity and a new website, giving Sonovein a new brand image that reflects innovation, clinical excellence, and ambition. In addition, two new product placement (PPU) contracts for Sonovein have been signed in Bulgaria and Spain, stepping up Theraclion's presence in Europe and expanding the installed base of the technology. Revenue for S1 2025 Theraclion's revenue for S1 2025 was €835K, up 89% compared to 2024 (€442K) (prior to the non-recurring adjustment of €680K related to the cancellation of Echopulse system sales in 2024). Consumables, which include recurring revenues from PPUs, was up 30% compared to S1 2024. Service revenues were up 232% over the same period. This strong momentum is a key indicator of increasing use of Sonovein by treatment centers and reflects the technology's sustained traction in the field. Combined, consumables and services — representing recurring revenue — was up 57% compared to 2024. Progress of the pivotal FDA clinical trial In the USA, the pivotal FDA-approved study for SONOVEIN® reached a major milestone in June 2025 with the on-schedule completion of the 12-month post-treatment patient follow-ups. Data analysis is currently underway, with results expected in September. Submission of the marketing authorization application to the FDA is planned for Fall 2025, with potential approval estimated for Q2 2026, subject to the FDA's processing time. This progress marks a critical strategic milestone in the work to access the world's largest market for venous disease treatment. Next financial publication: Theraclion will publish its interim financial results on October 29, 2025. About Theraclion Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and patients can immediately resume their routines. HIFU treatment concentrates therapeutic ultrasounds on an internal focal point from outside the body. Theraclion is developing SONOVEIN®, a CE-marked, a robotic platform for HIFU varicose vein treatment, which could replace millions of surgical procedures every year. In the USA, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the USA. Based in Malakoff (Paris), the Theraclion team comprises some 30 people, most of them involved in technological and clinical development. Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI: 9695007X7HA7A1GCYD29
Business Wire
5 hours ago
- Business Wire
Bradford Health Services Earns Coveted "Great Place To Work"® Certification
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Bradford Health Services, a leading provider of drug and alcohol addiction treatment across the Southeastern U.S., today announced it has been officially certified as a Great Place To Work®. This recognition, awarded by the global authority on workplace culture, underscores Bradford Health's commitment to building a supportive, inclusive, and high-trust environment for its more than 1,600 U.S.-based employees. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. Share Bradford Health achieved certification with 67% of employees reporting a positive experience at work, surpassing the typical U.S.-based company average of 57%. Key areas of strength highlighted by employees include: 89% agree they are entrusted with significant responsibilities. 86% say their work has special meaning beyond being 'just a job,' and that they felt welcomed upon joining. 84% affirm they feel they make a difference in the organization. 82% report they can be themselves at work. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. 'We've built a culture where our people come first—where leaders exist to support, uplift, and empower our teams to live out our mission with purpose and compassion.' Great Place To Work® conducts its evaluations using its proprietary Trust Index™ survey and Trust Model™, which assess culture across five pillars: credibility, respect, fairness, pride, and camaraderie. About Bradford Health Services With 40 years of experience, Bradford Health Services operates addiction treatment centers in Alabama, Florida, Mississippi, North Carolina, Tennessee, and Texas. The organization is accredited by The Joint Commission and delivers evidence-based care at every stage of the recovery journey. About Great Place To Work® Certification Great Place To Work® Certification ™ is the gold standard for workplace culture recognition. Based on anonymous employee feedback, the certification recognizes organizations that foster high levels of trust, pride, and camaraderie.
New York Post
5 hours ago
- New York Post
Llamas could help treat schizophrenia: study
Talk about a llama-zing discovery. They're known for their fluffy furs and sassy stares, but scientists have discovered that llamas may also be the key to treating schizophrenia. And this isn't even the first time this year that llamas have been at the heart of curing a scary health issue. Advertisement They're known for their fluffy furs and sassy stares, but it turns out llamas may also be the key to treating schizophrenia. Cavan for Adobe – In a mind-blowing new study, French researchers have developed a molecule from llama antibodies that could one day help patients with schizophrenia overcome cognitive deficits — a major hurdle that existing treatments fail to address. Scientists at the Institute of Functional Genomics in Montpellier have engineered what's called a nanobody — a tiny antibody fragment found in camelids like llamas — that can activate a specific glutamate receptor responsible for brain signaling. What's more, this molecule can cross the blood-brain barrier — a major challenge in drug development — and go straight to work on neural receptors when injected via a vein or muscle. Advertisement Researchers tested the llama-derived nanobody in two preclinical models of schizophrenia. Just one injection was enough to boost brainpower in mice, showing a clear and sustained improvement in cognitive function for up to a week. More research will be needed to see if this presents a promising new avenue of treatment for schizophrenia and, if so, whether or not this can be expanded to treat other psychiatric and neurodegenerative diseases. Advertisement The findings were published Wednesday in the journal Nature. Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps. elnariz – Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps. More than 200,000 people in the US are living with schizophrenia, for which there is no cure. Advertisement The cause of schizophrenia is still unknown, but research suggests a combination of genetic and environmental factors are likely to encourage its onset, which typically occurs between the ages of 16 and 30. Schizophrenia is primarily treated with antipsychotics, which target some of the more severe symptoms like hallucinations and delusions, but fail to do much for cognitive function. This new study offers hope for repairing cognition, as opposed to simply managing symptoms. 'In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia,' paper author and CNRS molecular biologist Jean-Philippe Pin told Newsweek. 'For development as a therapeutic tool, more safety and bioavailability studies are needed. Production of large quantities of high quality must be set up to start human studies. For these two possibilities, either a company takes up our project or we find investors to create a startup company.' Meanwhile, another study published last month found that llamas may also hold the secret weapon to curing COVID — and it's also in their nanobodies. 'This work provides a strong foundation for developing next-generation antibodies that could be vital in combating not only current but also future coronavirus threats,' said Dr. Xavier Saelens, senior author of the study and a principal investigator at the VIB-UGent Center for Medical Biotechnology in Belgium.
